



Resistant Hypertension (RH) is defined as blood pressure 
(BP) that remains above the recommended target in spite of 
the use of three antihypertensive drugs with synergistic actions 
at maximum recommended and tolerated doses, one of which 
should preferably be a diuretic, or when four or more different 
antihypertensive drugs are used, even when BP is controlled1. 
True RH must be differentiated from pseudo-resistance, 
which occurs due to non-adherence to treatment, inadequate 
blood pressure measurements, use of inadequate doses or 
therapeutic regimens, or the occurrence of white-coat effect2.
Control of hypertension in Brazil and worldwide 
An average of 30% of the adult population has high blood 
pressure (HBP), about 1.2 billion people in the world3. In 
Brazil, 14 population-based studies (1994-2009) revealed 
low levels of BP control (19.6%)4.
The fact that hypertension control doubled in the U.S. from 
1988 to 2008 (27.3% vs. 53.5%)5, and increased fivefold in 
Canada from 1992 to 2009 (13.2% vs. 64.6%)6, reflects important 
advances in HBP detection and treatment in these countries.
Incidence and prevalence of resistant hypertension
Daugherty et al. found an RH incidence of 1.9% in an 
18-month follow-up of hypertensive patients who started 
treatment. This study involved a large cohort of ethnically 
diverse patients and took treatment adherence into account, 
therefore excluding pseudo-resistance7.
Although the exact RH prevalence has not been established 
yet, it is estimated that the condition affects 12-15% of 
individuals with high blood pressure8. Data from the National 
Health and Nutrition Examination Survey (NHANES) in the 
period of 2003 to 2008 showed that 12.8% of hypertensive 
patients taking antihypertensive drugs in the United States had 
RH9. Egan et al.10 noted that these percentages have increased 
in the United States. 
Factors contributing to resistant hypertension
Both systolic and diastolic hypertension may be resistant, 
the former being more prevalent1. Causal factors include 
increased sensitivity to salt, fluid overload (due to increased 
sodium intake, chronic nephropathy, or inadequate diuretic 
therapy), exogenous substances (non-hormonal anti-
inflammatory drugs, corticosteroids, oral contraceptives, 
sympathomimetics, chemotherapy drugs, antidepressants, 
immunosuppressants, decongestants, anorectics, alcohol, and 
cocaine), and secondary causes of hypertension (emphasizing 
primary aldosteronism, obstructive sleep apnea, chronic 
nephropathy, and renal artery stenosis)11,12.
The following characteristics are predominant in patients 
with resistant hypertension: older age, African descent, obesity, 
left ventricular hypertrophy, diabetes mellitus, chronic kidney 
disease, metabolic syndrome, increased salt intake, and 
reduced physical activity. It should be noted that the white-
coat effect is present in about 30% of RH patients1,13.
Prognostic aspects
RH is a condition with difficult clinical management and high 
cardiovascular risk. Most epidemiological studies evaluating 
the prognosis of resistant hypertension have limitations such 
as lack of uniformity in definitions and information on drugs 
used, inclusion of cases of pseudo-hypertension, as well as 
insufficient follow-up time and exclusion of young patients1,14. 
The prognosis is especially associated with the following 
factors: prolonged exposure to high blood pressure, increased 
blood pressure, target organ damage and mineralocorticoid 
(aldosterone) excess, and high rates of sodium intake15-17. 
Several studies show that aldosterone is an important marker 
of  cardiovascular disease severity18.
Ambulatory Blood Pressure Monitoring (ABPM) is an 
important prognostic marker, especially nocturnal blood 
pressure and 24-hour pulse pressure14,19,20.
Assessment flowchart 
The first step in the investigation of resistant hypertension 
is the exclusion of causes of pseudo-resistance, such as 
inadequate blood pressure measurement technique, poor 
adherence to treatment, pseudo-hypertension, and white-
coat effect1 (Figure 1). ABPM is the method of choice for 
confirmation of inadequate blood pressure control, but if this 
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is not available, Home Blood Pressure Monitoring (HMBP) or 
Self-Monitoring Blood Pressure (SMBP) are useful13, 21. 
Target organ damage and associated comorbidities should 
be investigated with specialized tests, because they influence 
the stratification of cardiovascular risk, and are prognostic 
markers22,23. 
Among the causes of pseudo-resistance, poor adherence 
is the major challenge. Therapeutic inertia, prescription of 
insufficient doses or non-synergistic medications, and poor 
doctor-patient relationship should be observed, as well as 
the search for agents that can interfere with blood pressure 
control. If the goal to be achieved is not reached within six 
months, a short period hospitalization should be considered24.
Approximately 30% to 50% of patients underestimate their 
sodium intake. The impact of sodium restriction on resistant 
hypertension is well established, and the determination of 
24-hour urinary sodium excretion should be performed as 
control16. The diagnosis of secondary hypertension should be 
thoroughly searched for in resistant hypertension. 
Blood pressure measurement
The use of an accurate technique for BP measurement is 
essential for the accurate diagnosis of resistant hypertension. 
The patient should be quietly seated for five minutes before the 
measurement, with the back supported and the arm at heart 
level. A cuff suitable for the arm circumference should be used 
(width/length proportion 1:2, and width and length of rubber 
cuff corresponding to 40% and 80% of arm circumference, 
respectively)25. A minimum of three readings should be taken 
at intervals of at least one minute, and the average of the last 
two measurements should be used if the difference between 
them is less than or equal to 4 mm Hg. BP should be measured 
in both arms, and the arm with the higher pressures should 
be used in future measurements. If the difference between 
the arms is greater than 15 mmHg for systolic blood pressure 
and/or 10 mmHg for diastolic blood pressure, atherosclerotic26 
vascular disease should be investigated. BP measurements in 
supine and upright positions should be taken in the follow-up 
evaluations to assess orthostatic hypotension.
ABPM
ABPM is an important tool in the diagnosis of a major 
cause of pseudo-resistance, in which individuals with a BP 
supposedly higher than the goal in the clinician’s office have 
a normal ABPM. This difference between office and awake 
ABPM blood pressure measurements is called white-coat 
effect. Very high pressure levels may be a limitation to the test, 
because of patient discomfort. In these situations, HMBP and 
SMBP are alternative options.
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HMBP 
HMBP is an indirect method of recording the blood 
pressure, with three measurements in the morning and three 
at night for five days4. HMBP indications are basically the same 
as for ABPM, but HMBP may be better tolerated in patients 
with very high blood pressure. HMBP can also identify the 
white-coat effect, therefore excluding or confirming RH.
SMBP 
SMBP is a measurement method usually performed at home 
by patients or family members. The main advantage of SMBP 
is the possibility of obtaining a more accurate estimate of the 
actual blood pressure values, because they are obtained in the 
environment where the patients live, provided that validated and 
calibrated equipment is used. Table 1 shows a list of pressure 
values considered normal for hypertension and for white-coat 
effect in Office, ABPM, HMBP, and SMBP measurements.
Target organ lesions
Vascular and brain disorders
Vascular abnormalities may be present in the early 
stages of hypertensive disease. RH is associated with more 
severe vascular dysfunction, as assessed by endothelium-
dependent vasodilation and serum biomarkers, which may 
explain an absence of nocturnal blood pressure decline and 
a higher pulse pressure during ABPM27,28. There is a close 
relationship between high levels of BP, endothelial dysfunction 
and increased vascular stiffness in patients with resistant 
hypertension, demonstrated by a reduction in flow-mediated 
vasodilatation and in a high pulse wave velocity. In this 
population, higher levels of aldosterone are also observed29,30.
The nervous system may be affected early in RH and it is 
mostly benefited from adequate BP control. Vascular changes 
are universal, and cerebral vessels are affected relatively 
early in the hypertensive process. Retinal microvascular 
abnormalities reflect what happens in the brain. A retinal 
exam may show microaneurysms, hemorrhages, hard and soft 
exudates, pathological arteriovenous crossings, and arterial 
wall thickening. 
Carotid stenosis, intracranial and aortic arch atherosclerosis, 
and cardiac lesions may be responsible for ischemic or 
thromboembolic phenomena. The uncontrolled hypertension 
can lead, over time, to small brain aneurysms that may rupture, 
causing large subarachnoid or intracerebral hemorrhage.31 
Lacunar infarcts are small, generally less than 2.0 cm in 
diameter, and they result from obstruction of small perforating 
vessels, and may be responsible for progressive dementia.
Cardiac disorders 
The main cardiac damage in patients with resistant 
hypertension is left ventricular hypertrophy (LVH). In Brazil, the 
prevalence of LVH, diagnosed by echocardiography, in patients 
with resistant hypertension is 83.3%32. In these patients, ECG 
changes with T wave inversion and ST segment depression 
in leads V5 and V6 indicate a worse prognostic33,34. LVH is an 
important independent risk factor for cardiovascular morbidity 
and mortality, increasing the risk by 1.5 times in individuals 
with this lesion35. This condition predisposes the development 
of heart failure, ventricular tachyarrhythmias, ischemic or 
embolic stroke, and atrial fibrillation. In LVH, decreased 
coronary flow reserve, arterial wall stiffening, and endothelial 
dysfunction lead to a significant myocardial ischemia. In 
these individuals, since they present macrovascular and 
microvascular endothelial dysfunction, chest pain symptoms 
should be taken seriously, even when angiography shows no 
evidence of relevant coronary disease36. 
Kidney disorders
Renal lesions are common and occur early, with 
hemodynamic changes secondary to glomerular mass loss, but 
which determine hypertrophy and hyperfiltration of residual 
normal nephrons. 
The so-called “benign” hypertensive nephrosclerosis 
is characterized by arteriosclerosis and arteriolosclerosis, 
hyalinosis, tubular-interstitial lesions, and focal segmental or 
global glomerulosclerosis37. On the other hand, myointimal 
hyperplasia and fibrinoid necrosis are described as 
abnormalities that may eventually lead to the lesions caused 
by malignant hypertension37. 
There are several risk factors that may contribute to the 
development and progression of hypertensive nephrosclerosis: 
age (over 50), male gender, genetic predisposition and ethnicity 
(African descent), duration and severity of hypertension, low 
socioeconomic status, severity of proteinuria, severity of renal 
dysfunction, dyslipidemia; and other aggressors: smoking 
habit, excessive salt and protein intake in the diet, use of anti-
inflammatory drugs, antibiotics and other nephrotoxic agents38.
Phenotype of resistant hypertensive patients
Advanced age is a major factor related to the difficulty in 
achieving systolic BP goals. Alongside, the Framingham study 
found a correlation between difficulty of BP control and the 
presence of a higher baseline systolic blood pressure39. LVH 
and obesity are also strong predictors of failure to control 
hypertension, the latter being more related to difficulties 
Table 1 - Office, ABPM, HMBP, and SMBP blood pressure values in mmHg, characterizing normal and white-coat effect values 
Office ABPM (awake average) HMBP SMBP
Normal < 140/90 ≤ 130/85 ≤ 130/85 ≤ 130/85
Hypertension ≥ 140/90 > 130/85 > 130/85 > 130/85
White-coat effect Difference between office and awake ABPM (or HMBP) measurements 
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in controlling the diastolic blood pressure. High rates of 
sodium intake18, chronic kidney disease (glomerular filtration 
rate ≤60 mL/min), diabetes, and African descent complete 
the list of clinical characteristics associated with difficulty of 
BP control1. Other conditions have been associated, such 
as: a) presence of silent and early damage in target organs 
such as microalbuminuria23,40,41, LVH42,43, obstructive sleep 
apnea syndrome46-44, and  metabolic syndrome47.  Although 
a cause and effect relationship with resistant hypertension has 
not been fully defined yet for the last two conditions, some 
studies have indicated the existence of common mechanisms 
for obesity, metabolic syndrome, diabetes, sleep disorders and 
inflammatory activity in hypertensive patients, in general48,49. 
There is a common association among positive screening 
test for hypercortisolism and diabetes, advanced age and a 
non-dipper pattern in a resistant hypertensive population50. 
Furthermore, RH patients with type 2 diabetes have a more 
severe autonomic dysfunction associated with higher levels of 
body mass index and reduced plasma levels of adiponectin51. 
The presence of elevated plasma levels of aldosterone has 
been identified as relevant to the failure of BP control52.
Secondary hypertension
There is no evidence to suggest the true prevalence 
of secondary causes among subjects with resistant 
hypertension. However, the likelihood of secondary 
causes among patients with severe and/or difficult-to-
control hypertension is notably greater. Obstructive Sleep 
Apnea (OSA), Primary Aldosteronism (PA), Chronic Renal 
Parenchymal Disease (CRPD), Renovascular Hypertension 
(RVH), Pheochromocytoma (PHEO), Cushing’s syndrome 
(CS), Coarctation of the Aorta (CoA), thyroid disorders and 
the use of some drugs that affect the blood pressure, illicit 
drugs and alcohol abuse are the most common secondary 
forms of resistant hypertension. OSA is highly prevalent; in 
our country, it was found in 64% of patients with resistant 
hypertension53. There was a prevalence of 20% of PA in 
the resistant hypertensive population54. Atherosclerotic 
RVH is present in 12.5% of resistant hypertensive patients 
aged over 50 years55. PHEO is associated with paroxysmal 
(30% of cases) or resistant hypertension with or without 
paroxysms in 50% to 60% of the cases56. The possibility of 
a secondary cause is one of the key points of the evaluation 
of hypertensive patients. In RH, however, greater emphasis 
should be put on the investigation of secondary causes, 
and specific exams and tests should be conducted in 
suspected cases. Table 2 shows the main causes of secondary 
hypertension, suggestive symptoms and the main diagnostic 
methods for the investigation of these conditions.
Nonpharmacological measures
The use of nonpharmacological measures is of great 
importance in the treatment of RH1. Despite the small number 
of studies evaluating the effectiveness of these measures, they 
have proven to be effective in the treatment of hypertensive 
patients in general, and this benefit seems to be higher in 
severe hypertensive patients than in those with mild/moderate 
hypertension. Therefore, patients with resistant hypertension 
should be counseled about the importance of reducing salt 
in the diet, losing weight, exercising regularly and practicing 
moderation in consumption of alcohol1,4.
Salt restriction: a high intake of dietary sodium demonstrably 
contributes to resistance to antihypertensive therapy. Elderly 
patients of African descent or with impaired renal function 
are especially sensitive to salt. Despite a low sodium diet 
moderately lower (3.7 to 7.0/0.9 to 2.5 mmHg) blood pressure 
in hypertensive patients in general57-60, those with resistant 
hypertension are particularly salt-sensitive. A study comparing 
the effects of a low sodium diet in patients with resistant 
hypertension showed that a diet containing approximately 
2.5 g salt/day can reduce BP by 23.0/9.0 mmHg. This study 
demonstrates that the reduction in salt intake (3.0-4.0 g 
salt/day) is essential in managing patients with resistant 
hypertension. It is important to emphasize how difficult it is 
to reduce dietary salt intake to the recommended values61.
Alcohol consumption: There is a direct relationship 
between the amount of alcohol consumed and blood pressure 
levels, so that excessive consumption of alcohol contributes 
significantly to the difficulty in controlling BP. Men who 
consume excessive amounts of alcohol (≥ 4 doses/day) are 
50% more likely to have BP above goal63. Aguilera et al.64 
evaluated the effect of abstinence from alcohol on blood 
pressure in deep-rooted drinkers, and found an average 
reduction of 7.2 and 6.6 mmHg, respectively, in systolic and 
diastolic BP over 24 hours64. In the same study, the prevalence 
of hypertension among participants decreased from 42% to 
12%. Moderate consumption of alcohol (≤ 20 g of ethanol 
or two doses per day) or total abstinence is recommended 
for deep-rooted drinkers.
Weight loss: obesity is associated with stimulation of 
the sympathetic nervous system, retention of salt and sleep 
apnea1,4. Therefore, obesity is associated with elevated blood 
pressure and resistance to antihypertensive treatment, and 
weight loss significantly reduces blood pressure. Patients with 
Body Mass Index (BMI) ≥30 kg/m2 have 50% higher chance 
of presenting uncontrolled BP than those with normal BMI 
(<25  kg/m2)65. A cross-sectional study with 45,125 patients 
revealed that, compared to those with normal BMI, patients 
with BMI >40 kg/m2 were three times more likely to require 
the use of three anti-hypertensive and five times more likely 
to need four drugs to achieve adequate control of BP66. 
Therefore, weight loss must always be sought in RH patients 
who present overweight or obesity. 
Physical activity: the available data point to a clear 
beneficial effect of regular physical activity in reducing 
BP1,67. The practice of aerobic exercises has a direct effect on 
lowering blood pressure and improves the metabolic profile. 
Resistance exercises also seem to have a beneficial effect on 
blood pressure, and should complement aerobic activity4,67. 
Therefore, patients with resistant hypertension should be 
encouraged to perform light to moderate physical activity after 
medical evaluation. The training program should not be started 
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Pharmacological treatment
The purpose of the pharmacological treatment of resistant 
hypertension is the reduction of cardiovascular risk. For this it 
is recommended to achieve the following BP goal: Office BP 
of 130/80 mmHg; 24-hour ABPM of 125/75 (ideal), 130/80 
mmHg may be tolerable; and HMBP of 130/80 mmHg13,19.
Verification of the antihypertensive regimen, assessing the 
combination, dosage and proper optimization of medications, 
correcting sub-doses or lack of adherence, and investigating 
the use of other classes of drugs that may interfere with the 
antihypertensive efficacy, should always be conducted to 
confirm the diagnosis of RH1. 
The rationale in choosing a regimen of antihypertensive 
drugs is to block all the possible mechanisms involved in 
blood pressure elevation. The combination of a drug that 
blocks the Renin-Angiotensin-Aldosterone System (RAAS), 
which may be an Angiotensin Converting Enzyme Inhibitor 
(ACEI) or an Angiotensin II AT1 Receptor Blocker (ARB), 
associated with a prolonged action dihydropiridine Calcium 
Channel Antagonist (CCA) and a thiazide diuretic, is often 
very effective and well tolerated clinically. This is considered 
the best triple combination, the more effective and synergistic 
one in achieving the recommended BP goal68,69. The use of a 
renin inhibitor as a drug that blocks the RAAS is less evident 
in terms of cardiovascular protection.
Fluid overload seems to be the most frequent pathophysiological 
mechanism in this population. Thiazide diuretics with prolonged 
action are recommended. Chlorthalidone, having greater 
antihypertensive efficacy than hydrochlorothiazide, and a plasma 
half-life estimated between 45 and 60 hours, is preferably 
recommended for RH patients with preserved renal function.1 
Loop diuretics are indicated if creatinine clearance is below 30 
mL/min. Due to its short duration of action (3 to 6 hours), it is 
recommended that they are used twice a day. 
Table 2 - Main causes of secondary hypertension, symptoms and signs, initial screening tests and diagnostic confirmation exams
Cause Suggestive clinica findings Screening tests Advanced diagnostic exams
OSA Snoring, episodes of apnea during sleep, daytime sleepiness, obesity, short neck
Berlin Questionnaire, Epworth 
sleepiness scale
Polysomnography (apnea-hypopnea 
index > 5 events/hour)
Primary aldosteronism Hypokalemia (spontaneous or induced by diuretics), paresthesias
Aldosterone/renin > 30 (Renin < 
1 and Aldo > 12) 
Computed tomography (nodule or hyperplasia), 
fludrocortisone test, saline infusion 
test, measurement of aldosterone
by adrenal vein catheterization
Chronic Kidney Disease facial edema, uremic breath, anemia, diabetes or family history of nephropathy
serum creatinine, glomerular 
filtration rate estimated by 
formulas (< 60 mL/min), 
microalbuminuria, proteinuria
Renal ultrasound (signs of 
renal parenchymal disease)
Renovascular hypertension
Abdominal bruit, >30% increase in serum 
creatinine with the use of ACEI, ARB or DRI; 
hypertension in young or elderly patients 
Renal artery Doppler (peak 
velocity ≥ 150 cm/s; renal-
aortic velocity ratio ≥ 3); 
tomoangiography/MRI of 
renal arteries  
Renal arteriography (lesion over 60% / 
translesional gradient > 20 mmHg)
Cushing's syndrome moon facies, hump, purple striae, central obesity, hirsutism 
24-hour urinary cortisol, plasma 
cortisol suppression test after 
low dose of dexamethasone 
(overnight), nocturnal 
salivary cortisol
Computed tomography of the adrenals 
and/or MRI of the hypophysis
Pheochromocytoma
headache, palpitations, sweating, 
tachycardia, orthostatic hypotension, 
syncope 
Serum metanephrines, urinary 
metanephrines, plasma 
catecholamines
MRI of the adrenals, MIBG 
scintigraphy, PET scan
Coarctation of the aorta
Reduction of pulses in the legs, the pressure 
difference greater than 20 mmHg between 
arms and legs, blow on the back.
Magnetic resonance angiography 
of the aorta, echocardiography Aortography
Hyperthyroidism and 
hypothyroidism 
Tachy/bradycardia, increased sensitivity 
to heat/cold, myxedema, diarrhea or 
constipation, menstrual abnormalities 
TSH, free T4 Thyroid ultrasound
Substances that can raise blood pressure elevation 
Investigate the use of: non-narcotic analgesics, anti-inflammatory non-steroid, 
corticosteroids, sympathomimetic agents (decongestants, appetite suppressants, 
cocaine), stimulants (methylphenidate, dexmethylphenidate, dextroamphetamine, 
amphetamine, methamphetamine, modafinil), alcohol, oral contraceptives, cyclosporine, 
erythropoietin, licorice, herbs (ephedra, Mahuang)
OSA: obstructive sleep apnea syndrome; ACE: converting enzyme inhibitor; ARB: angiotensin receptor blocker; DRI: direct renin inhibitor; TSH: thyroid-stimulating hormone.
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Several classes of antihypertensive drugs compete to the 
position of a fourth drug, but so far no comparative study 
has been conducted with them to demonstrate superiority 
in terms of anti-hypertensive efficacy or cardiovascular 
protection. The addition of mineralocorticoid receptor 
blockers to the treatment with conventional drugs is 
the four-drug regimen with greater visibility and it 
significantly reduces blood pressure in patients with 
resistant hypertension. In an ASCOT sub-study, the 
participants who completed the study and did not have a 
controlled BP with three antihypertensive agents received 
spironolactone (mean 25 mg) as a fourth drug. After a mean 
follow up of 1.3 years, the systolic and the diastolic BP 
decreased 21.9 and 9.5 mmHg, respectively. The reduction 
in blood pressure with spironolactone occurs regardless of 
the aldosterone/plasma renin activity ratio70. 
The choice of additional drugs to the four-drug combination 
is empirical and should be individualized4,71 (Figure 2). 
Hospitalization is not recommended for the investigation of 
secondary hypertension or therapy optimization, but this is a 
strategy that can be used when available, if after six months 
of therapy optimization the recommended BP goal is not 
achieved, being an alternative verification of adherence and 
sodium restriction. 
Although there is no evidence of reduction of 
cardiovascular risk, chronotherapy is an adjuvant strategy 
in patients on three drugs and with the goal BP not reached 
prior to the combination of a fourth agent; in these cases 
an ACC may be used in the night period72. This strategy 
has proven effective in the implementation of sleep blood 
pressure reduction and decrease.
Adherence can be implemented by simplifying the 
treatment regimen with the use of fixed drug combinations. 
Even if the BP goal is not achieved, pressure values should be 
as close as possible to the recommended goal.
New treatments
The lack of evidence about the best therapy in RH led 
to the development of new treatments which are being 
prioritarily tested in patients with poor response to the initial 
pharmacological treatment. 
Direct stimulation of the carotid sinus
The increased sympathetic tone and decreased 
parasympathetic tone increase peripheral vascular resistance 
to sodium retention, reduce renal blood flow and glucose 
metabolism, and contribute negatively to myocardial 
remodeling73. The chronic stimulation of baroreceptors may 
exert beneficial effects on blood pressure.
The Rheos Baroreflex Activation Therapy System is a 
programmable device that resembles a surgically implanted 
pacemaker and consists of a pulse generator. The Rheos Pivotal 
Trial found no significant benefits with this system, and further 
studies are expected to show the benefits of this device74.
Renal sympathetic denervation 
Renal sympathetic nerves contribute to the development and 
maintenance of hypertension, and renal sympathetic activity 
is exacerbated in hypertensive patients. Endovascular renal 
sympathetic ablation was evaluated in a case series of patients 
Figure 2  – Flowchart of the treatment of resistant hypertension.
Treatment Flowchart
Non-pharmalogical treatment
↓ Salt ↓ Alcohol ↓ Obesity ↓ Sleep apnea
Pharmacological treatment
ACEI/ARB + CCA + Thiazide-type diuretic
(pref. chlorthalidone)
Fourth drug: Spironolactone 25/50 mg per day
Betablocker Vasodilator 
Central  Alpha-2 Agonist




First Brazilian position on resistant hypertension
Arq Bras Cardiol 2012;99(1):576-585
with resistant hypertension. Over two years, there was a decrease 
of 32 mmHg and 14 mmHg in the SBP and DBP, respectively, with 
a very low rate of complications.75 In the study Symplicity-2, in 
six months, the difference in pressure drop between the groups 
was 33 mmHg and 11 mmHg in SBP and DBP, respectively. In 
the intervention group, 84% of patients had a reduction of at 
least 10 mmHg, whereas in the control group, this proportion 
was 35%. There were no major complications related to the 
described procedure. These findings show that endovascular 
ablation of the renal artery is a promising procedure in the context 
of RH, but further studies are necessary to show the possibility of 
reproducible results and better dissemination of the technique. 
Use of Continuous Positive Airway Pressure (CPAP) 
The effects of CPAP on RH were tested in a clinical trial 
with 75 patients who had their RH condition confirmed by 
ABPM and who had an apnea-hypopnea index (AHI) ≥ 15/
h76. After a three-month follow-up, only 24h-DBP reduced 
significantly in the group treated with CPAP (4.9 ± 6.4 mmHg 
vs. 0.1 ± 7.3 mmHg in control). The antihypertensive effect 
was more pronounced in those who tolerated the use of CPAP 
for more than 5.8 h/day. All the evidence concerning the 
antihypertensive effect of CPAP and the results of this trial in 
resistant hypertension indicate that this option can be tried as 
an adjunctive treatment in patients with AHI greater than 15/h, 
especially those who tolerate their use for more than 5 h/day. 
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